National Science Council

Zih Yuan Tang Biotechnology Co., Ltd.

National Taiwan University

Ming-Jai Su

Shoei-Sheng Lee

Chao-Min Hsu

Che-Ming Teng

Chi-Huan Yeh

Chien-Chih Chen

Yueh-Hsiung Kuo

Sheu-Meei Yu

Lung-Jr Lin

Ling-Wei Hsin

Sheng-Fa Tsai

Cheng-Yen Tsai

Chi-Tun Ruan

The present invention provides a method for treating an ocular disease such as age-related macular degeneration (AMD), diabetic retinopathy (DR) or macular edema (ME), which comprises administering to a subject in need thereof a composition comprising a therapeutically effective amount of beauvericin.

Method for treating ocular diseases

The present invention provides a method for activating the AMP-dependent protein kinase (AMPK) in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I, preferably salsolinol or reticuline. The pharmaceutical composition is able to activate AMPK, and thus is effective in the regulation of cell growth and metabolism, and the treatment of AMPK associated diseases.

Isoquinoline alkaloid derivative for activating AMP-dependent protein kinase

The present invention is related to a method for diabetic wound healing comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I, preferably salsolinol.

Use of isoquinoline derivatives for diabetic wound healing

A compound is provided. The compound includes a formula of: 

8-phenylisoquinolines and pharmaceutical composition used in treatment for sepsis

The present invention provides a catechol-based derivative and a pharmaceutical acceptable salt therefrom and a solvate therefrom. A pharmaceutical composition for preventing or treating diabetics and ischemics, comprising a catechol-based derivative of formula (I) and at least one selected from the group consisting of a pharmaceutical excipient, a diluent and a carrier. 

Catechol-based derivatives for treating or preventing diabetics

The present invention discloses thaliporphine and its derivatives for the treatment and/or prophylaxis of cardiac diseases, including cardiac arrhythmia, myocardial ischemia or myocardial infarction, and sudden death caused by cardiac arrhythmia or acute myocardial infarction.

Uses of thaliporphine or its derivatives in treatment of cardiac diseases and preparation of same

Novel secoaporphine compounds having the formula I ##STR1## wherein a) R.sub.1, R.sub.2 and R.sub.3, R.sub.4 are each methyl group; or b) R.sub.1, R.sub.2, and R.sub.4 are each methyl group; R.sub.3 is benzyl, ethyl or allyl; or c) R.sub.1, R.sub.2, and R.sub.3 are each hydrogen, R.sub.4 is methyl; or d) R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 is benzyl, R.sub.4 is methyl; or e) R.sub.1 and R.sub.2 are each hydrogen, R.sub.3 is cyano, R.sub.4 is methyl group, and a salt thereof with a pharmaceutically acceptable acid. The novel compounds are useful in the treatment of arrhythmia.

Secoaporphine compound on arrhythmia

A method of arrhythmia with an effective amount of dicentrine or other alkaloids extracted from Lindera oldhammii (megaphylla) Hemsl.

Use of dicentrine and its derivatives for the treatment of arrhythmia

A method for the treatment of hypertension, arrhythmia, thrombosis or/and atherosclerosis with an effective amount of dicentrine or other alkaloids extracted from Lindera oldhammii (megaphylla) Hemsl.

Growing community of inventors

Taipei, Taiwan

Ming-Jai Su